Regulatory

Short delay in the clinical phase II study

Scandion Oncology A/S (“Scandion Oncology”) informs about a short delay in the clinical phase II study with SCO-101 in drug resistant colorectal cancer. The delay is due to external events outside the influence of Scandion Oncology and is unrelated to the treatment with SCO-101.

CEO Nils Brunner comments

At Scandion Oncology we are doing everything possible to secure that this delay will be as short as possible. We expect study activities to be back on track within the next few weeks and we are exploring solutions to keep the preset timelines”.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on March 9, 2020.

Scandion Oncology A/S is a biotechnology company that addresses and tackles one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.